NEW YORK, Feb. 16 Reportlinker.com announces that a new market research report is available in its catalogue:
UCB S.A.: PharmaVitae Profile
Advertisement
http://www.reportlinker.com/p0177525/UCB-SA-PharmaVitae-Profile.html
Introduction
This analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Advertisement
Reasons to Purchase
*Benchmark UCB's performance against key rivals in the prescription pharmaceutical sector
*Determine the extent to which UCB's next-generation of CNS medications will protect revenues from the decline of its Keppra franchise
*Examine the long-term sales potential offered by Cimzia after its long-awaited approvals for Crohn's disease and rheumatoid arthritis
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 7
UCB: PharmaVitae forecasts at a glance 8
Strategic insight 9
Epilepsy launches central to overcoming Keppra generics 9
Vimpat and Rikelta in line to replace Keppra as UCB's next-generation AED medications 9
Biopharmaceutical business model yet to deliver growth 11
SWOT analysis 12
Table of Contents 13
Table of figures 15
Chapter 3 Quarterly news update 16
Product developments 16
Deals and alliances 18
Product deals 18
Company announcements 19
Chapter 4 Company introduction 20
Key findings 20
Background 21
Key corporate developments 21
M&A history 22
Celltech 22
Schwarz Pharma 23
Chapter 5 Company sales 24
Key findings 24
Prescription pharmaceutical sales and growth rate analysis, 2002-14 25
Product analysis 26
Product analysis, 2002-08 27
Product analysis, 2008-14 30
Therapy area analysis 33
Geographic analysis 35
Launch/core/expiry analysis 37
Explanation of launch/core/expiry analysis 37
Launch analysis, 2008-14 38
Core analysis, 2008-14 39
Expiry analysis, 2008-14 40
Generics analysis, 2008-14 41
Launch/core/expiry configuration, 2008-14 42
Molecule type analysis 43
Externalization analysis 45
Chapter 6 Company financials 47
Key findings 47
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 48
Operating costs and profit analysis 49
Operating costs and profit analysis, 2002-08 50
Operating cost ratio and profit margin analysis, 2002-08 51
Operating cost ratio and profit margin analysis, 2008-14 52
Operating costs and profit analysis, 2008-14 53
Chapter 7 Key products and competitors 54
Key findings 54
Overview 55
Central nervous system 56
Keppra/Keppra XR 56
Overview 57
Sales forecast 58
Gold standard anti-epileptic drug 58
Launch of Keppra XR in September 2008 represents a clear lifecycle management strategy 59
Generics will erode a significant portion of the Keppra franchise's market share 60
Japan market penetration offers franchise some growth opportunity 60
Rikelta 61
Overview 62
Sales forecast 63
Next-generation version of Keppra currently in phase III trials 63
Datamonitor expects brivaracetam's target population to be treatment-refractory epilepsy patients 64
Neupro 65
Overview 66
Sales forecast 67
Novel Parkinson's formulation 67
Product recall in the US expected to slow uptake 67
Improved compliance and symptom control set to drive uptake 68
Vimpat 70
Overview 71
Sales forecast 72
Vimpat is the newest member of UCB's antiepileptic franchise 72
Approval as an adjunctive epilepsy treatment set to boost UCB offering 73
Neuropathic pain use rejected by FDA 73
Cannibalization of sales by brivaracetam represents a key threat to Vimpat 74
Immunology & inflammation 75
Cimzia 75
Overview 76
Sales forecast 77
UCB's novel anti-TNF mAb finally gets green light 77
Non-responder patient population and pricing offer key route to uptake 78
Cimzia is back in Phase III for Crohn's disease in the EU - Datamonitor updated its forecast to reflect impact of a Cimzia launch 78
Chapter 8 Appendix 80
R&D pipeline 80
References 81
Abbreviations 81
Exchange rates 83
About Datamonitor 84
About Datamonitor Healthcare 84
Datamonitor consulting 84
Disclaimer 86
List of Tables
Table 1: UCB - PharmaVitae forecasts at a glance 8
Table 2: UCB key product developments, 2009 16
Table 3: UCB deals and alliances, 2009 18
Table 4: UCB company announcements, 2009 19
Table 5: UCB product portfolio overview ($m), 2002-08 27
Table 6: UCB product portfolio overview ($m), 2008-14 30
Table 7: UCB prescription pharmaceutical sales by therapy area ($m), 2008-14 34
Table 8: UCB prescription pharmaceutical sales by geographic region ($m), 2008-14 36
Table 9: UCB launch portfolio overview ($m), 2008-14 38
Table 10: UCB core portfolio overview ($m), 2008-14 39
Table 11: UCB expiry portfolio overview ($m), 2008-14 40
Table 12: UCB generics portfolio overview ($m), 2008-14 41
Table 13: UCB prescription pharmaceutical sales by molecule type ($m), 2008-14 44
Table 14: UCB prescription pharmaceutical sales by source ($m), 2008-14 46
Table 15: Total UCB sales by business unit ($m), 2002-08 48
Table 16: UCB operating revenue/cost analysis ($m), 2002-08 50
Table 17: UCB operating cost ratio analysis (% of total revenues), 2002-08 51
Table 18: UCB operating cost ratio analysis (% of total revenues), 2008-14 52
Table 19: UCB operating revenue/cost analysis ($m), 2008-14 53
Table 20: Key products overview 55
Table 21: Keppra/Keppra XR: overview 57
Table 22: Keppra/Keppra XR: sales forecast ($m), 2008-14 58
Table 23: Rikelta: overview 62
Table 24: Rikelta: sales forecast ($m), 2008-14 63
Table 25: Neupro: overview 66
Table 26: Neupro: sales forecast ($m), 2008-14 67
Table 27: Vimpat: overview 71
Table 28: Vimpat: sales forecast ($m), 2008-14 72
Table 29: Cimzia: overview 76
Table 30: Cimzia: sales forecast ($m), 2008-14 77
Table 31: UCB's R&D pipeline (Phase I-registration) 80
Table 32: Exchange rates, 2009 83
List of Figures
Figure 1: The PharmaVitae Explorer 3
Figure 2: UCB prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6
Figure 3: UCB's financial performance ($m), 2002-14 7
Figure 4: UCB's epilepsy portfolio, sales ($m), 2002-14 10
Figure 5: UCB SWOT analysis 12
Figure 6: UCB prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 25
Figure 7: Key product sales ($m), 2002-14 26
Figure 8: UCB key sales growth drivers and resistors ($m), 2002-08 29
Figure 9: UCB key sales growth drivers and resistors ($m), 2008-14 32
Figure 10: UCB prescription pharmaceutical sales by therapy area ($m), 2002-14 33
Figure 11: UCB prescription pharmaceutical sales by geographic region ($m), 2002-14 35
Figure 12: UCB launch/core/expiry configuration ($m), 2008-14 42
Figure 13: UCB prescription pharmaceutical sales by molecule type ($m), 2002-14 43
Figure 14: UCB prescription pharmaceutical sales by source ($m), 2002-14 45
Figure 15: UCB operating revenue/cost analysis ($m), 2002-14 49
To order this report:
Pharmaceutical Industry: UCB S.A.: PharmaVitae Profile
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg Reportlinker Email: [email protected] US: (805)652-2626 Intl: +1 805-652-2626
SOURCE Reportlinker
